NYSE: ENOVEnovis Corp Stock
$21.79-1.02 (-4.47%)
Updated Feb 5, 2026
ENOV Price
$21.79
Fair Value Price
N/A
Market Cap
$1.25B
52 Week Low
$21.00
52 Week High
$44.97
P/E
-0.9x
P/B
0.62x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.23B
Earnings
-$1.37B
Gross Margin
58.4%
Operating Margin
-57.67%
Profit Margin
-61.2%
Debt to Equity
1.19
Operating Cash Flow
$217M
Beta
1.25
Next Earnings
Feb 26, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ENOV Overview
Enovis Corporation is a medical technology company focused on orthopedics. It manufactures medical devices for patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, or sports-related injuries. Formerly known as Colfax Corporation, Enovis was founded in 1995 and is headquartered in Wilmington, DE.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENOV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Industrial Machinery
Industry Rating
A
ENOV
Ranked#31 of 69
Ranked#31 of 69
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $78.78 | A | |
| $48.00 | A | |
| $48.77 | A |
Be the first to know about important ENOV news, forecast changes, insider trades & much more!
ENOV News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENOV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENOV is good value based on its book value relative to its share price (0.62x), compared to the US Specialty Industrial Machinery industry average (6.78x)
P/B vs Industry Valuation
ENOV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ENOV due diligence checks available for Premium users.
Valuation
ENOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.9x
Industry
23.47x
Market
41.19x
ENOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
6.78x
ENOV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENOV's financial health
Profit margin
Revenue
$548.9M
Net Income
-$571.1M
Profit Margin
-104.1%
ENOV's Earnings (EBIT) of -$1.29B... subscribe to Premium to read more.
Interest Coverage Financials
ENOV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$2.4B
Debt to equity
1.19
ENOV's short-term assets ($1.28B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENOV's long-term liabilities ($1.83B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENOV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ENOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$82.6M
Investing
-$56.1M
Financing
-$36.9M
ENOV's operating cash flow ($217.08M)... subscribe to Premium to read more.
Debt Coverage Financials
ENOV vs Specialty Industrial Machinery Stocks
Enovis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.